Construction and immunological evaluation of dual cell surface display of HIV-1 Gag and Salmonella enterica serovar typhimurium FliC in Lactobacillus acidophilus for vaccine delivery

Clinical and Vaccine Immunology

Volumn 19, Issue 9, 2012, Pages 1374-1381

  Kajikawa, Akinobu ^a   Zhang, Lin ^a   Long, Julie ^b   Nordone, Shila ^b   Stoeker, Laura ^b   LaVoy, Alora ^a   Bumgardner, Sara ^b   Klaenhammer, Todd ^b   Dean, Gregg ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VECTOR; BINDING PROTEIN; FLAGELLIN; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; MUCUS BINDING PROTEIN; SIGNAL PEPTIDE; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; CELL MATURATION; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG DELIVERY SYSTEM; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC RECOMBINATION; HETEROLOGOUS EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOSTIMULATION; LACTOBACILLUS ACIDOPHILUS; MOUSE; MUCOSAL IMMUNITY; MYELOID DENDRITIC CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SALMONELLA TYPHIMURIUM; SEROTYPE; VACCINATION;

ADMINISTRATION, ORAL; AIDS VACCINES; ANIMALS; BACTERIAL VACCINES; CELL SURFACE DISPLAY TECHNIQUES; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; FLAGELLIN; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HUMANS; INTESTINAL MUCOSA; LACTOBACILLUS ACIDOPHILUS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; SALMONELLA TYPHIMURIUM; VACCINES, SYNTHETIC;

EID: 84865974136     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00049-12     Document Type: Article

References (42)

1. Adar Y, et al. 2009. A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 27:2099-2107.
2. Aliprantis AO, et al. 1999. Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2. Science 285:736-739.
3. Altermann E, et al. 2005. Complete genome sequence of the probiotic lactic acid bacterium Lactobacillus acidophilus NCFM. Proc. Natl. Acad. Sci. U. S. A. 102:3906-3912. (Pubitemid 40388530)
4. Bargieri DY, et al. 2008. New malaria vaccine candidates based on the Plasmodium vivax merozoite surface protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine 26:6132-6142.
5. Bermúdez-Humarán LG, et al. 2005. A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J. Immunol. 175:7297-7302. (Pubitemid 41713425)
6. Brightbill HD, et al. 1999. Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors. Science 285:732-736.
7. Christensen HR, Frøkiaer H, Pestka JJ. 2002. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J. Immunol. 168:171-178. (Pubitemid 34014116)
8. Derby N, Martinelli E, Robbiani M. 2011. Myeloid dendritic cells in HIV-1 infection. Curr. Opin. HIV AIDS 6:379-384.
9. Drakes M, Blanchard T, Czinn S. 2004. Bacterial probiotic modulation of dendritic cells. Infect. Immun. 72:3299-3309. (Pubitemid 38697752)
10. Duong T, Miller MJ, Barrangou R, Azcarate-Peril MA, Klaenhammer TR. 2011. Construction of vectors for inducible and constitutive gene expression in Lactobacillus. Microb. Biotechnol. 4:357-367.
11. Franchi L, et al. 2006. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat. Immunol. 7:576-582. (Pubitemid 43797338)
12. Girard MP, Osmanov S, Assossou OM, Kieny M-P. 2011. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development. Vaccine 29:6191-6218.
13. Grangette C, et al. 2005. Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc. Natl. Acad. Sci. U. S. A. 102:10321-10326. (Pubitemid 41023369)
14. Hanahan D. 1983. Studies on transformation of Escherichia coli with plasmids. J. Mol. Biol. 166:557-580. (Pubitemid 13027898)
15. Hayashi F, et al. 2001. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099-1103. (Pubitemid 32391041)
16. Honko AN, Sriranganathan N, Lees CJ, Mizel SB. 2006. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect. Immun. 74:1113-1120. (Pubitemid 43185549)
17. Huleatt JW, et al. 2007. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25:763-775. (Pubitemid 44856106)
18. Kajikawa A, Masuda K, Katoh M, Igimi S. 2010. Adjuvant effects for oral immunization provided by recombinant Lactobacillus casei secreting biologically active murine interleukin-1β. Clin. Vaccine Immunol. 17:43-48.
19. Kajikawa A, et al. 2011. Dissimilar properties of two recombinant Lactobacillus acidophilus strains displaying Salmonella FliC with different anchoring motifs. Appl. Environ. Microbiol. 77:6587-6596.
20. Kang JY, et al. 2009. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 31:873-884.
21. Kasturi SP, et al. 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470:543-547.
22. Lebeer S, Vanderleyden J, de Keersmaecker SCJ. 2010. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat. Rev. Microbiol. 8:171-184.
23. Lei H, et al. 2011. Evaluation of the oral immunization effect of recombinant HA1 displayed on Lactococcus lactis surface and combined with mucosal adjuvant CTB. Clin. Vaccine Immunol. 18:1046-1051.
24. Matsuguchi T, et al. 2003. Lipoteichoic acids from Lactobacillus strains elicit strong tumor necrosis factor alpha-inducing activities in macrophages through Toll-like receptor 2. Clin. Vaccine Immunol. 10:259-266. (Pubitemid 36314450)
25. McDonald WF, et al. 2007. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J. Infect. Dis. 195: 1607-1617. (Pubitemid 46799218)
26. Miao EA, et al. 2006. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat. Immunol. 7:569-575. (Pubitemid 43797337)
27. Miao EA, et al. 2010. Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proc. Natl. Acad. Sci. U. S. A. 107:3076-3080.
28. Mizel SB, Bates JT. 2010. Flagellin as an adjuvant: cellular mechanisms and potential. J. Immunol. 185:5677-5682.
29. Mohamadzadeh M, Duong T, Sandwick SJ, Hoover T, Klaenhammer TR. 2009. Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proc. Natl. Acad. Sci. U. S. A. 106:4331-4336.
30. Mohamadzadeh M, et al. 2005. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc. Natl. Acad. Sci. U. S. A. 102:2880-2885. (Pubitemid 40299885)
31. Pino O, Martin M, Michalek SM. 2005. Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica serovar Typhimurium to potentiate mucosal and systemic responses. Infect. Immun. 73:6763-6770. (Pubitemid 41368843)
32. Querec T, et al. 2006. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203:413-424. (Pubitemid 43290850)
33. Ryu YH, et al. 2009. Differential immunostimulatory effects of Gram-positive bacteria due to their lipoteichoic acids. Int. Immunopharmacol. 9:127-133.
34. Steidler L, et al. 1998. Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect. Immun. 66:3183-3189. (Pubitemid 28303115)
35. Stoeker L, et al. 2011. Assessment of Lactobacillus gasseri as a candidate oral vaccine vector. Clin. Vaccine Immunol. 18:1834-1844.
36. Uematsu S, Akira S. 2009. Immune responses of TLR5(+) lamina propria dendritic cells in enterobacterial infection. J. Gastroenterol. 44:803-811.
37. Uematsu S, et al. 2008. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat. Immunol. 9:769-776. (Pubitemid 351859160)
38. Vaccari M, Poonam P, Franchini G. 2010. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev. Vaccines 9:997-1005.
39. Wells J. 2011. Mucosal vaccination and therapy with genetically modified lactic acid bacteria. Annu. Rev. Food Sci. Technol. 2:423-445.
40. Wells JM, Mercenier A. 2008. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat. Rev. Microbiol. 6:349-362. (Pubitemid 351552656)
41. Xin KQ, et al. 2003. Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Vaccine 102:223-228.
42. Zeuthen LH, Fink LN, Frøkiaer H. 2008. Toll-like receptor 2 and nucleotide-binding oligomerization domain-2 play divergent roles in the recognition of gut-derived lactobacilli and bifidobacteria in dendritic cells. Immunology 124:489-502. (Pubitemid 351962545)